Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27820668
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27820668
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Virulence
2017 ; 8
(2
): 222-236
Nephropedia Template TP
Virulence
2017[Feb]; 8
(2
): 222-236
PMID27820668
show ga
Invasive fungal infections remain a major cause of morbidity and mortality in
immunocompromised patients, and such infections are a substantial burden to
healthcare systems around the world. However, the clinically available
armamentarium for invasive fungal diseases is limited to 3 main classes (i.e.,
polyenes, triazoles, and echinocandins), and each has defined limitations related
to spectrum of activity, development of resistance, and toxicity. Further,
current antifungal therapies are hampered by limited clinical efficacy, high
rates of toxicity, and significant variability in pharmacokinetic properties. New
antifungal agents, new formulations, and novel combination regimens may improve
the care of patients in the future by providing improved strategies to combat
challenges associated with currently available antifungal agents. Likewise,
therapeutic drug monitoring may be helpful, but its present use remains
controversial due to the lack of available data. This article discusses new
facets of antifungal therapy with a focus on new antifungal formulations and the
synergistic effects between drugs used in combination therapy.
|*Drug Discovery
[MESH]
|Antifungal Agents/*chemistry/*therapeutic use
[MESH]
free
free
free
